Skip to Content
Merck

Key Documents

View All Documentation

C3993

Carvedilol

≥98% (HPLC), β-adrenergic blocker, solid

Synonym(s):

1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol, BM-14190

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C24H26N2O4
CAS Number:
72956-09-3
Molecular Weight:
406.47
UNSPSC Code:
12352200
PubChem Substance ID:
329775050
NACRES:
NA.77
MDL number:
MFCD00864692
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Carvedilol, ≥98% (HPLC), solid

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white to off-white

solubility

DMSO: >20 mg/mL

originator

GlaxoSmithKline

SMILES string

OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC

InChI

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

InChI key

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRB1(153), ADRB2(154), ADRB3(155)

Application

Carvedilol has been used:
  • as a β blocker to determine its effect on hypoxia inducible factor (HIF)-mediated erythropoiesis under hypoxia in vivo
  • as a βAR antagonist for inhibition of bARs
  • as a β-blocker to examine airway mechanics in fungus-challenged mice

Biochem/physiol Actions

Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity.
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Carvedilol

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Warning

hcodes

H373,H411

Hazard Classifications

Aquatic Chronic 2 - STOT RE 2

target_organs

Liver,spleen,Uterus (including cervix),Adrenal gland

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000531544
0000531544
0000494293
0000494293
0000396235

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Long-acting beta agonists enhance allergic airway disease
Knight JM, et al.
Testing, 10(11), e0142212-e0142212 (2015)
Hypoxia sensing through beta-adrenergic receptors
Cheong HI, et al.
JCI insight, 1(21) (2016)
V J Thanawala et al.
British journal of pharmacology, 172(20), 4833-4846 (2015-07-28)
Our previous studies have shown the β2 -adrenoceptor and its endogenous ligand, adrenaline, are required for development of the asthma phenotype in murine asthma models. Chronic administration of some, but not other, β-blockers attenuated the asthma phenotype and led us
View All Related Papers